Organization Overview
Alternative names
anastrozole (arimidex) (3 trials)
capecitabine (xeloda) (8 trials)
carboplatin (paraplatin) (39 trials)
cyclophosphamide (cytoxan) (9 trials)
durvalumab (imfinzi) (4 trials)
etoposide (vepesid) (4 trials)
exemestane (aromasin) (3 trials)
fluorouracil (efudex) (14 trials)
acalabrutinib (calquence) (1 trial)
aflibercept (zaltrap) (1 trial)
alemtuzumab (campath) (1 trial)
arsenic trioxide (trisenox) (2 trials)
atezolizumab (Tecentriq) (1 trial)
autologous mononuclear stem cell (2 trials)
azacitidine (vidaza) (1 trial)
bendamustine (treanda) (4 trials)
besifloxacin (besivance) (1 trial)
bevacizumab (avastin) (36 trials)
bifidobacterium animalis (1 trial)
bortezomib (velcade) (7 trials)
cabazitaxel (jevtana kit) (2 trials)
carfilzomib (kyprolis) (2 trials)
cetuximab (erbitux) (2 trials)
cisplatin (platinol) (2 trials)
daunorubicin (cerubidine) (1 trial)
elotuzumab (empliciti) (1 trial)
enzalutamide (xtandi) (2 trials)
epirubicin (ellence) (3 trials)
eptifibatide (integrilin) (1 trial)
erlotinib (tarceva) (14 trials)
estramustine (emcyt) (2 trials)
everolimus (zortress) (10 trials)
Filgrastim (neupogen) (2 trials)
fludarabine (fludara) (2 trials)
fulvestrant (faslodex) (6 trials)
gatifloxacin (Zymar) (1 trial)
ibritumomab tiuxetan (Zevalin) (2 trials)
lenalidomide (revlimid) (4 trials)
lorlatinib (lorbrena) (1 trial)
methylprednisolone (medrol) (1 trial)
mitoxantrone (novantrone) (1 trial)
moxifloxacin (avelox) (1 trial)
necitumumab (portrazza) (1 trial)
octreotide (sandostatin) (1 trial)
ofatumumab (arzerra) (3 trials)
oxaliplatin (eloxatin) (12 trials)
palbociclib (ibrance) (1 trial)
panitumumab (vectibix) (3 trials)
panobinostat (farydak) (7 trials)
pazopanib (votrient) (3 trials)
pembrolizumab (keytruda) (4 trials)
pemetrexed (alimta) (10 trials)
pomalidomide (pomalyst) (1 trial)
prednisone (meticorten) (2 trials)
quizartinib (VANFLYTA) (1 trial)
ramucirumab (cyramza) (1 trial)
regorafenib (stivarga) (2 trials)
rituximab (rituxan) (10 trials)
rovalpituzumab tesirine (1 trial)
sorafenib (nexavar) (10 trials)
teclistamab (Tecvayli) (1 trial)
temozolomide (temodar) (3 trials)
thalidomide (Thalomid) (2 trials)
tocilizumab (actemra) (1 trial)
topotecan (hycamtin) (12 trials)
toremifene (fareston) (1 trial)
trastuzumab (herceptin) (11 trials)
venetoclax (venclexta) (1 trial)
Acute Coronary Syndrome (Phase 3)
Adenocarcinoma (Phase 2)
Angina, Unstable (Phase 3)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoid Tumor (Phase 2)
Carcinoma (Phase 3)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Ovarian Epithelial (Phase 3)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Small Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 3)
Communicable Diseases (Phase 2)
Corneal Ulcer (Phase 2)
Digestive System Neoplasms (Phase 2)
Endometrial Neoplasms (Phase 1)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
GATA2 Deficiency (Phase 1)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 1)
Graft vs Host Disease (Phase 2)
Head and Neck Neoplasms (Phase 2)
Hodgkin Disease (Phase 2)
Hypersensitivity (Phase 3)
Hypoxia (Phase 1)
Infarction (Phase 3)
Infections (Phase 2)
Inflammatory Breast Neoplasms (Phase 2)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 1)
Lymphoma, T-Cell, Peripheral (Phase 1)
Melanoma (Phase 2)
Meningioma (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 1)
Myocardial Infarction (Phase 3)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Neoplasms, Second Primary (Phase 2)
Neoplasms, Unknown Primary (Phase 3)
Neuroendocrine Tumors (Phase 2)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 2)
Preleukemia (Phase 2)
Prostatic Neoplasms (Phase 2)
Rectal Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Stomach Neoplasms (Phase 2)
Syndrome (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Ulcer (Phase 2)
Urinary Bladder Neoplasms (Phase 1)